OCEANIC-STROKE Phase 3 Trial Advances Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention
核心洞察
The phase 3 OCEANIC-STROKE trial is evaluating asundexian, a factor XIa (搜索) inhibitor, for secondary prevention in patients with non-cardioembolic ischemic stroke (搜索) or high-risk TIA (搜索).
The trial enrolled over 12,000 patients in just two years, including adults without upper age limits and those with NIHSS scores up to 15 or ABCD² scores ≥6.
Previous PACIFIC-STROKE phase 2 data showed asundexian 50 mg reduced symptomatic recurrent stroke, particularly in patients with atherosclerosis (搜索), with favorable safety profile.
The phase 3 OCEANIC-STROKE trial represents a significant advancement in stroke prevention research, evaluating asundexian, a factor XIa (搜索) inhibitor, for secondary prevention following non-cardioembolic ischemic stroke (搜索) or transient ischemic attack (TIA (搜索)). With more than 12,000 patients randomized in just two years, the trial showcases the growing global capacity for collaborative stroke research and the urgency to find safer, more effective alternatives to existing antithrombotic regimens.
Trial Design and Patient Population
The OCEANIC-STROKE trial was designed with specific eligibility criteria to capture real-world stroke populations. The study includes patients with NIHSS scores up to 15 or high-risk TIA (搜索) with ABCD² scores of 6 or higher. Notably, the trial includes adults without an upper age limit, reflecting the demographics of actual stroke populations in clinical practice.
Dr. Mike Sharma emphasizes the rationale behind the patient selection: "The inclusion of patients with documented atherosclerosis (搜索) or embolic-appearing infarcts was informed by prior data and aimed to identify those most likely to benefit from factor XIa (搜索) inhibition."
Addressing Unmet Medical Need
The trial targets a significant gap in stroke prevention therapy. For patients without cardioembolic sources, aspirin remains the primary long-term therapy option, highlighting an unmet therapeutic need in this population. The OCEANIC-STROKE program aims to provide safer, more effective alternatives to existing antithrombotic regimens.
Foundation from PACIFIC-STROKE Phase 2 Results
The phase 3 trial builds upon promising findings from the PACIFIC-STROKE phase 2 trial (NCT04304508), the first study to evaluate a factor XIa (搜索) inhibitor in stroke patients. While the composite MRI endpoint in PACIFIC-STROKE was neutral, important clinical findings emerged that shaped the current phase 3 program.
Key Phase 2 Findings
The PACIFIC-STROKE trial demonstrated a reduction in symptomatic recurrent stroke with asundexian 50 mg, particularly among patients with atherosclerosis (搜索). These findings directly influenced both the dose selection for OCEANIC-STROKE and the inclusion criteria focusing on patients with vascular disease.
Equally important was the favorable safety profile observed in the phase 2 trial. The study showed no meaningful rise in serious bleeding events, which reinforced confidence in advancing asundexian to phase 3 development.
Clinical Implications
The OCEANIC-STROKE trial represents a data-driven approach to antithrombotic development. The phase 2 results helped establish optimal dosing at 50 mg and identified patient populations most likely to benefit from factor XIa (搜索) inhibition. For clinicians, these results underscore how translational, data-driven trial design can refine therapeutic development and accelerate progress toward safer secondary prevention strategies.
The rapid enrollment of over 12,000 patients demonstrates both the clinical need for improved stroke prevention therapies and the research community's commitment to addressing this challenge through collaborative international efforts.